Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug Administration announced Friday.
May 26, 2021
0
1
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors ...
Apr 22, 2021
0
57
A Phase 3 clinical trial showed a new medication that interferes with part of the immune system that causes inflammation was more effective than treatment with glucocorticoids ("steroids" such as prednisone) in keeping patients ...
Feb 17, 2021
0
13
Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and Drug ...
Dec 23, 2020
0
5
Lung cancer patients with a specific genetic alteration lived longer and were protected against metastasis to the brain when treated early with the drug lorlatinib (Lorbrena), according to a study led by researchers at Massachusetts ...
Nov 18, 2020
0
20
The risk of serious adverse effects on the blood status and bone marrow of patients during chemotherapy can be predicted by a model developed at Linköping University, Sweden. This research may make it possible to use genetic ...
Nov 12, 2020
0
44
Lung cancer continues to be the most deadly solid cancer in the world, despite the fact that survival rates have been improving over the past decade. However, African American patients have worse outcomes and shorter lifespans ...
Oct 28, 2020
1
1
Sharing a home with a pet appeared to act as a buffer against psychological stress during lockdown, a new survey shows.
Sep 25, 2020
0
647
An immunotherapy and a targeted treatment have been recommended for use on the NHS in Scotland, but a third treatment was rejected.
Sep 16, 2019
0
4
A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according ...
Sep 8, 2019
0
5
